Search
Diazoxide
go.drugbank.com/drugs/DB01119ApprovedInvestigationalDiazoxide is a non-diuretic benzothiadiazine derivative that activates ATP-sensitive potassium channels. It is chemically related to thiazide diuretics but does not inhibit carbonic anhydrase and does not have chloriuretic or natriuretic...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsTolbutamide
go.drugbank.com/drugs/DB01124ApprovedMedications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C18 SubstratesSynonyms: 1-Butyl-3-(p-tolylsulfonyl)urea, 1-p-Toluenesulfonyl-3-butylureaDutasteride
go.drugbank.com/drugs/DB01126ApprovedInvestigationalDutasteride is an oral synthetic 4-azasteroid commonly marketed under the trade name Avodart. It is a novel dual 5α-reductase inhibitor that works by blocking both isoforms of 5α-reductase enzymes in a potent, selective, and irreversible...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesCarvedilol
go.drugbank.com/drugs/DB01136ApprovedInvestigationalCarvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker. It is currently used to treat heart failure, left ventricular dysfunct...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesLevofloxacin
go.drugbank.com/drugs/DB01137ApprovedInvestigationalLevofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic ofloxacin. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remai...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSulfinpyrazone
go.drugbank.com/drugs/DB01138ApprovedA uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 SubstratesNefazodone
go.drugbank.com/drugs/DB01149ApprovedWithdrawnNefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic i...
Categories: P-glycoprotein inducers, P-glycoprotein inhibitorsCrisaborole
go.drugbank.com/drugs/DB05219ApprovedInvestigationalCrisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis. This non-steroidal agent is efficacious in improving disease severity, reducing the risk of ...
Categories: Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2C8 InhibitorsCobimetinib
go.drugbank.com/drugs/DB05239ApprovedInvestigationalCobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been app...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesDexlansoprazole
go.drugbank.com/drugs/DB05351ApprovedDexlansoprazole is a new-generation proton pump inhibitor (PPI) used for the management of symptoms associated with gastroesophageal reflux disease (GERD) and erosive esophagitis. Dexlansoprazole is the R-enantiomer of DB00448, which is ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates